瑞舒伐他汀对冠状动脉支架术后患者的干预研究

Intervention with Rosuvastatin for Patients after Coronary Stenting

目的:探讨瑞舒伐他汀对冠脉支架术后患者的影响。方法:选择我院2010年2月至2012年3月收治的急性冠脉综合征行冠脉支架植入术患者114例,随机分为观察组(n=57)和对照组(n=57);观察组患者术后给予常规用药加用瑞舒伐他汀,对照组患者术后给予常规用药,两组均治疗6个月。治疗结束后复行冠脉造影,观察比较两组患者的冠脉支架再狭窄率、心绞痛再发率及血脂和C反应蛋白(CRP)水平变化及不良反应。结果:观察组冠脉支架再狭窄率、心绞痛再发率明显低于对照组,差异有统计学意义(P<0.05);两组用药后血脂和CRP水平均比用药前明显改善,用药后观察组TC、TG、LDL-C、CRP水平明显低于对照组,HDL-C水平明显高于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:瑞舒伐他汀可显著改善冠脉支架术后再狭窄、心绞痛再发,有效调节血脂和抑制炎症,值得临床进一步推广。

To investigate the effect of rosuvastatin for patients with coronary stenting.Method： 114 patients with acute coronary syndrome admitted to our hosoital from Feb. 2010 to Mar. 2012 were randomly divided into observation group （ n = 571 and control group （ n = 577. The observation group was treated with rosuvastatin based on conventional medication and the control group was treated with conventional medication. After 6 months of treatment, all patients were observed by coronary arteriography. Restenosis rate of coronary stent, recurrence rate of angina, levels of blood lipids and C-reactive protein （CRP） , and adverse reactions were observed and compared between the two groups. Result： The restenosis rate of coronary stent, recurrence rate of angina of the observation group were significantly lower than those of the control group （ P〈0.05 ）. The levels of lipids and CRP were improved of all patients. The levels of TC, TG, LDL-C and CRP of the observation group were significantly lower than those of the control group, and the level of HDL-C was significantly higher than that of the control group （ P〈0.05）. There was no significant difference of the incidence of adverse reactions between the two groups （ P〉0.05 }. Conehtsion： Rosuvastatin is effective to improve coronary stent restenosis and angina recurrence. It can also regulate blood lipids and inhibit inflammation, which is worthy of further promotion.